Company intelligence / Profile preview
SK Biopharmaceuticals
- Ownership
- Public · 326030
- Employees
- ~750
- Development stage
- Commercial
Overview
SK Biopharmaceuticals has successfully developed two FDA-approved drugs—cenobamate for partial-onset seizures in adults (marketed as XCOPRI®) and solriamfetol for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Cenobamate has been launched in the US through its own sales network—the first Korean biotech to do so—and approved/marketed in Europe via partners. The company’s pipeline spans CNS disorders and oncology with multiple assets at various clinical stages.
- Therapeutic areas
- OncologyPsychiatryNeurology
- Modalities
- Small moleculesTargeted protein degradationRadiopharmaceutical therapyCell & gene therapy
- Industry
- Biotech
Drug pipeline
19 assets18 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $4.6B
- Total revenue
- $522.1M
- Enterprise value
- $4.3B
Beyond the preview
Go deeper on SK Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SK Biopharmaceuticals.